Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells.
Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multidifferentiation, as well as by their anti-inflammatory, antiproliferative, immunomodulatory, trophic, and proangiogenic properties. Various diseases have been treated by MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Moreover, autologous MSCs can be affected by the disease status of patients, compromising their use. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of the host (patient) medical conditions on MSCs is important for assuring the safety and efficacy of cell-based therapies. This review provides relevant information regarding factors to consider for the clinical application of MSCs.
Department of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, Spain.
Natalia
N
Escacena
Newbiotechnic (NBT), Bollullos de la Mitación, 41110 Seville, Spain.
Elena
E
Quesada-Hernández
Department of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, Spain.
Vivian
V
Capilla-Gonzalez
Department of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, Spain ; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08036 Barcelona, Spain.
Bernat
B
Soria
Department of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, Spain ; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08036 Barcelona, Spain.
Abdelkrim
A
Hmadcha